UNSPSC 51372805: Eptazocine hydrobromide

This classification denotes an analgesic agent with the molecular structure C15H21NO.BRH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 865626Y4ON chemically known as 1,6-methano-1h-4-benzazonin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, hbr (1:1), (1s,6s)-, but more commonly known as eptazocine hydrobromide, which bears US NIH Compound Identifier 155705. European Medicines Agency schedules Eptazocine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01924MIG.

UNSPSC 51372805 Eptazocine hydrobromide is a Commodity code covering pharmaceutical products, but the recent state and local procurement activity under this code does not reflect eptazocine purchases. Instead, Seminole County, Florida posted an IFB (Invitation for Bid) in June 2026 for naloxone and safe drug deactivation systems—opioid-overdose reversal agents and harm-reduction equipment unrelated to eptazocine, which is an analgesic. The mismatch between the code's nominal scope and actual procurement activity indicates this Commodity code shows little relevant recent buying signal for eptazocine or closely related analgesic compounds in state and local markets.

The single identified opportunity, Seminole County's IFB 60459723LAS with a response deadline of July 26, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors were required to submit bids through the county's e-Procurement Portal, include all shipping and delivery costs, hold workers' compensation and commercial general liability insurance, and comply with E-Verify requirements. The contract structure included an initial two-year term with a one-year renewal option and a three-month probationary period allowing termination at will. Potential FEMA funding introduced additional federal compliance obligations. Without additional recent opportunities demonstrating consistent state or local procurement of eptazocine or related pharmaceutical compounds, this code does not present a clear market opportunity for business development focus at this time.